Healthcare Focus Kurma Partners is a European venture capital group specializing in healthcare with a significant later-stage and early-stage portfolio, presenting opportunities to introduce portfolio services, co-investment conversations, and potential exit or collaboration discussions with their funded companies.

Active Fundraising With multiple dedicated funds (Kurma Biofund and Kurma Diagnostics) and recent fundraising activity such as Biofund IV close, there are opportunities to engage for limited partner (LP) relations, co-investment, and strategic partnerships aligned with fund cycles.

Strategic Exits Recent asset sales and investments, including the sale of PathoQuest stake to Charles River Laboratories and new investments in Memo Therapeutics, Alveus Therapeutics, and SciRhom, indicate a dynamic exit and value creation posture that could open avenues for advisory, collaboration, or secondary stake opportunities.

Digital Health Footprint Kurma Diagnostics focus suggests merits for partners in diagnostic tools, digital health platforms, radiology imaging, and theranostics alignment, presenting upsell opportunities for data analytics, software as a service, and clinical collaboration.

Global Collaboration Active involvement across European and North American healthcare startups with participation in international rounds signals potential for cross-border co-investments, technology licensing discussions, and expanded go-to-market partnerships with portfolio companies and curating advisory services.